QNTM — Quantum Biopharma Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1771885 · Ontario, Canada
Last close
$1.59
Market Cap
$10.22M
52W High
$12.42
52W Low
$1.33
ADV30
108,761
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,281,086 -3,252,967 14,391,885 3,647,072 8,297,670
Mar 2026 0 — -2,909,492 -13,560,299 14,926,075 4,341,908 16,345,974
Dec 2025 0 — -2,359,801 -3,026,467 11,160,909 1,905,357 6,058,294
Sep 2025 0 — -4,658,195 -5,319,029 14,153,228 445,944 6,646,480

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,485,545
Investing CF
$-3,498,569
Financing CF
$11,133,610
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.01
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-215,099,436
Inventory
$53,012
Receivables
$107,634
ST Investments
$210,708
EBIT TTM
$-24,980,343
Pretax Income TTM
$-25,297,132
Interest Exp TTM
$316,789
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -15,317,409 -26,175,286 11,160,909 6,058,294 6,924,475 -8,237,012
Dec 2024 0 -15,884,034 -14,202,724 17,119,224 6,678,992 11,480,538 -6,876,479
Dec 2023 0 -19,570,114 -17,902,179 17,474,828 4,565,566 13,236,763 -10,827,264
Dec 2022 0 -27,429,611 -23,606,828 38,410,656 7,868,436 30,542,220 -28,333,273
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.80

Peers — same industry

TickerNameMarket CapLastDaily %
HEPA Hepion Pharmaceuticals, Inc. $10.38M $0.12 —
RADX Radiopharm Theranostics Ltd $9.70M $0.67 —
HIND Vyome Holdings, Inc $10.84M $1.54 —
BIVI BIOVIE INC. $9.61M $1.00 —
PBM PSYENCE BIOMEDICAL LTD. $9.57M $2.51 —

News headlines (Yahoo Finance, 1h cache)

Quantum BioPharma (QNTM) Reports $12.22M in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial
2026-11-16 19:29 · Yahoo
Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up
2026-11-13 12:05 · Yahoo
Quantum BioPharma (QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control
2026-11-11 20:30 · Yahoo
Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares
2026-11-11 12:07 · Yahoo
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Thresho
2026-11-05 22:00 · Yahoo
Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth
2026-11-05 20:00 · Yahoo
Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise
2026-11-03 20:30 · Yahoo
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum B
2026-10-08 12:00 · Yahoo
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
2026-10-07 19:30 · Yahoo
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
2026-10-06 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.